Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dennis J Cotter

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Health Services Research|December 15, 2010
The effect of dialysis chains on mortality among patients receiving hemodialysisYi Zhang, Dennis J Cotter, Mae Thamer
Seminars in Dialysis|May 18, 2004
Improved survival with higher hematocrits: where is the evidence?Dennis J Cotter, Kevin Stefanik, Yi Zhang, et al.
Health Services Research|December 11, 2012
Organizational status of dialysis facilities and patient outcome: does higher injectable medication use mediate increased mortality?Yi Zhang, Mae Thamer, Onkar Kshirsagar, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 20, 2004
Epoetin requirements predict mortality in hemodialysis patientsYi Zhang, Mae Thamer, Kevin Stefanik, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 27, 2006
Factors influencing route of administration for epoetin treatment among hemodialysis patients in the United StatesMae Thamer, Yi Zhang, James Kaufman, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 12, 2014
Erythropoiesis-stimulating agent use among non-dialysis-dependent CKD patients before and after the trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) using a large US health plan databaseMae Thamer, Yi Zhang, Onkar Kshirsagar, et al.
Transplantation|May 7, 2014
Dialysis chains and placement on the waiting list for a cadaveric kidney transplantYi Zhang, Mae Thamer, Onkar Kshirsagar, et al.
Journal of Clinical Epidemiology|November 6, 2004
Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patientsDennis J Cotter, Kevin Stefanik, Yi Zhang, et al.
Kidney International|June 24, 2011
High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetesYi Zhang, Mae Thamer, James S Kaufman, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 1, 2015
Predicting Early Death Among Elderly Dialysis Patients: Development and Validation of a Risk Score to Assist Shared Decision Making for Dialysis InitiationMae Thamer, James S Kaufman, Yi Zhang, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Health Services Research|December 15, 2010
The effect of dialysis chains on mortality among patients receiving hemodialysisYi Zhang, Dennis J Cotter, Mae Thamer
Seminars in Dialysis|May 18, 2004
Improved survival with higher hematocrits: where is the evidence?Dennis J Cotter, Kevin Stefanik, Yi Zhang, et al.
Health Services Research|December 11, 2012
Organizational status of dialysis facilities and patient outcome: does higher injectable medication use mediate increased mortality?Yi Zhang, Mae Thamer, Onkar Kshirsagar, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 20, 2004
Epoetin requirements predict mortality in hemodialysis patientsYi Zhang, Mae Thamer, Kevin Stefanik, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 27, 2006
Factors influencing route of administration for epoetin treatment among hemodialysis patients in the United StatesMae Thamer, Yi Zhang, James Kaufman, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 12, 2014
Erythropoiesis-stimulating agent use among non-dialysis-dependent CKD patients before and after the trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) using a large US health plan databaseMae Thamer, Yi Zhang, Onkar Kshirsagar, et al.
Transplantation|May 7, 2014
Dialysis chains and placement on the waiting list for a cadaveric kidney transplantYi Zhang, Mae Thamer, Onkar Kshirsagar, et al.
Journal of Clinical Epidemiology|November 6, 2004
Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patientsDennis J Cotter, Kevin Stefanik, Yi Zhang, et al.
Kidney International|June 24, 2011
High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetesYi Zhang, Mae Thamer, James S Kaufman, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 1, 2015
Predicting Early Death Among Elderly Dialysis Patients: Development and Validation of a Risk Score to Assist Shared Decision Making for Dialysis InitiationMae Thamer, James S Kaufman, Yi Zhang, et al.
Pageof 2